Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Core Viewpoint - Merus N.V. is set to participate in the 24th Annual Needham Virtual Healthcare Conference, highlighting its focus on innovative oncology treatments [1]. Company Overview - Merus is an oncology company specializing in the development of full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics [3]. - Multiclonics are produced using industry-standard processes and have demonstrated characteristics similar to conventional human monoclonal antibodies, including long half-life and low immunogenicity in preclinical and clinical studies [3]. Event Details - Bill Lundberg, M.D., President and CEO of Merus, will engage in a fireside chat at the conference on April 8, 2025, at 8:45 a.m. ET [1]. - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2].